Abstract

Palbociclib (PAL) is an anti-cancer molecule that is highly selective for CDK4/6 inhibition and approved for the management of advanced breast cancer. Due to its down-and-out aqueous solubility and poor oral bioavailability, therapeutic applications have been compromised in the pharmaceutical field. The work aims to explore the physicochemical properties, aqueous solubility, dissolution rate, and in silico analysis of PAL complexed with β-cyclodextrin (β-CD) and 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) and to ascertain the implications of complexation on the in vitro anti-cancer activity of PAL. The two inclusion complexes (ICs) of PAL were prepared by the methodology of freeze-drying and further characterized by FT-IR, DSC, TGA, FESEM, and PXRD. The 1H NMR and 2D NMR revealed that a significant chemical shift was observed for the ICs as well and a correlation was seen between the CH3 of HP-β-CD with protons (ring C & D) of the pyrimidine and pyridine rings respectively. AL type graph was obtained depicting the KS value to be 625.4 M−1 and 3760 M−1 respectively for PAL-β-CD and PAL-HP-β-CD. Also, the aqueous solubility of PAL was improved by 31.05 and 37.99-fold respectively by both the ICs. The stoichiometric ratio of 1:1 was established by Job’s plot. Additionally, the results of in-silico studies were in correlation with the theoretical calculations. Further, it was found that the in vitro cytotoxicity investigation on MDA-MB-231 cells reported IC50 value for PAL-β-CD IC and PAL-HP-β-CD IC a 2.33– and 3.38-fold a lower IC50 value than PAL (IC50 = 9.55 ppm) which indicates higher cellular toxicity for both ICs in comparison to free PAL. Additionally, PAL-β-CD IC (41.99 ± 2.63 %) and PAL-HP-β-CD IC (57.33 ± 1.58 %) showed higher apoptosis than PAL (25.17 ± 1.27 %) also the cellular internalization was seen higher for both the ICs as well as the ROS formation, and MMP depolarization was evidenced.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call